Piper Sandler analyst Allison Bratzel maintains Humacyte (NASDAQ:HUMA) with a Neutral and maintains $4 price target.
Piper Sandler Maintains Neutral on Humacyte, Maintains $4 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.